Article Text

Download PDFPDF
Bilateral femoroplasty for cancer pain
  1. Marcela Samano-Garcia1,
  2. Victor M Silva-Ortiz2,
  3. Andres Rocha-Romero1,
  4. Jose Antonio Cortes-Lares1 and
  5. Ricardo Plancarte-Sanchez3
  1. 1 Pain Clinic, Mexico National Cancer Institute, Ciudad de Mexico, Ciudad de México, Mexico
  2. 2 Pain Management Department, Hospital Zambrano Hellion, San Pedro Garza Garcia, nl, Mexico
  3. 3 Mexico National Cancer Institute, Ciudad de Mexico, Ciudad de México, Mexico
  1. Correspondence to Dr Ricardo Plancarte-Sanchez, Mexico National Cancer Institute, Ciudad de Mexico, Ciudad de México, Mexico; plankyy2b{at}gmail.com

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Introduction

Cancer is one of the leading causes of morbidity and mortality worldwide. Cancer metastases to the skeletal system are located most often in the vertebrae (69%), followed by the pelvic bones (41%), long bones (usually the proximal femur) (25%) and skull (14%). Up to 84% of patients with cancer will experience bone pain. Patients with cancer-induced bone pain have moderate to severe pain, with a high risk of pathological fracture, particularly in proximal femoral lytic metastases. These harm quality of life, functional status and survival.1

Different techniques have been demonstrated to be effective; it is normally managed with nails or plates and screws. Percutaneous femoroplasty (PFP) has been shown to be feasible, safe and effective in controlling pain immediately and improving functionality in clinical trials. The stabilisation of the bone and the thermal action produced by the cement in theory, reduces metastatic activity and inhibits the local nociceptors.2

This study aims to present our experience with bilateral PFP in patients with cancer and evaluate its effectiveness and safety.

Study design

We performed a descriptive, longitudinal and retrospective study. The data collection was carried out from patients with cancer and lytic metastasis in the proximal femur treated with bilateral femoroplasty from 1 January 2010 to 24 December 2020; there were a total of 20 patients. The study …

View Full Text

Footnotes

  • Twitter @manejodeldolor, @drimdpainkiller

  • Contributors Study conception and design: RP-S and MS-G. Data collection: RP-S, MS-G and JACL. Analysis and interpretation of results: RP-S, MS-G, JACL, AR-R and VMS-O. Draft manuscript preparation: RP-S, MS-G, JACL, AR-R and VMS-O. All authors reviewed the results and approved the final version of the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.